In silico Toxicity Assessment and Quantification of Potential Genotoxic Impurity in Olmesartan Medoxomil Drug Substance using GC-MS/MS

This study was designed to assess the in silico toxicity of 4-chloromethyl-5-methyl-1,3-dioxol-2-one (4-CMMD) in olmesartan medoxomil (OLM) using sophisticated advanced analytical GC-MS/MS method. The developed GC-MS/MS method is more sensitive as well as selective, for trace level analysis of genotoxic impurity 4-chloromethyl-5-methyl-1,3-dioxol-2-one (4-CMMD) in olmesartan medoxomil (OLM). In silico genotoxicity of 4-CMMD have been confimed by ICH M7 guidelines and tested to be “POSITIVE” in both knowledge and statistical based approaches. The conditions of gas chromatographic separation and mass spectrometry were optimized on stationary phase DB-35MS, helium carrier gas as at a flow rate of 1.5 mL/min. Quantification was performed in multiple reaction monitoring (MRM) mode. The absence of interference at the retention time of 4-CMMD indicates that the newly developed approach is very specific and selective for accurately measuring trace levels of impurities. Additionally, this method provided linear results which were validated by linearity solutions, with concentrations ranging from 3.74 to 45.12 ppm and an observed coefficient of regression of 0.9981. Sensitivity results shows this method is more sensitive detection limit (DL) achieved at 1.23 ppm and quantification limit (QL) achieved at 3.74 ppm. The developed method is precise and accurate according to the precision results, which show RSD values < 10% and recovery > 90%, both of which are within acceptable standards. The solution stability of the samples was assessed at both room temperature and refrigerated settings, and it was found to be stable for a period of 48 h. As a result, this method has been employed for the intented purpose of quantifying 4-CMMD at the trace levels in testing laboratories, pharmaceutical analytical laboratories, and quality control laboratories.